Study of new drugs for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests new treatments for people with stage IV nonsquamous non-small cell lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It aims to find better options for those whose cancer has specific genetic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IV nonsquamous non-small cell lung cancer that has gotten worse after treatment with immunotherapy and platinum-based chemo.
- Your cancer must not have certain gene changes (EGFR, ALK, ROS1) that would allow for targeted therapy.
- You must have at least one tumor that can be measured on scans.
- You must be expected to live at least 3 more months and be in fairly good health (able to do daily activities).
- You must be 18 or older and have adequate organ function.
- You must provide a tumor tissue sample (either from a previous biopsy or a new one) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
This trial tests new drugs for people with advanced squamous non-small cell lung cancer that has gotten worse after standard treatments like immunotherapy and chemotherapy. The goal is to find better options for those who need them.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.